While Belviq leads, generic Xenical outnumbers the original

The impact of ‘Belviq’ was significant in the obesity treatment market. Ildong Pharmaceuticals’ Belviq(lorcaserin), which was first launched on March last year, recorded approximately KRW 14 billion sales in 10 months, continuing its flying performance and becoming a leading product in no time.   

The product was also expected to be a product of KRW 30 billion in a sense it has a high chance t...